EAM Investors’s Tourmaline Bio TRML Stock Holding History

EAM Investors’s Portfolio TRML Stock Details TRML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-24,585	Closed	-$644K	–	334
2023 Q4	$644K	Buy	+24,585	New	+$492K	0.11%	206

Other funds holding TRML

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Jennison Associates

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return

EAM Investors's TRML Position: Q1 2024 in Review

EAM Investors sold out of Tourmaline Bio (TRML) in Q1 2024, closing a stake of 24,585 shares — an estimated $644K sold.

EAM Investors first reported a position in TRML in Q4 2023 and held it in 1 quarter. The position peaked at $644K in Q4 2023. 96 funds tracked by Wall St. Rank hold TRML as of Q1 2024.

EAM Investors reported no remaining Tourmaline Bio position as of Q1 2024 after selling out during the quarter.
EAM Investors sold 24,585 Tourmaline Bio shares in Q1 2024, an estimated $644K.
EAM Investors first reported a position in Tourmaline Bio in Q4 2023 and held it in 1 quarter.
EAM Investors's Tourmaline Bio position peaked at $644K in Q4 2023.
96 funds tracked by Wall St. Rank held Tourmaline Bio as of Q1 2024.

Based on EAM Investors's 13F filing for Q1 2024, filed 13 May 2024.